ExpreS2ion Biotech Announces Pareto Securities Analyst Update on Q1 2025 Results and Clinical Trial Progress
Hørsholm, Denmark, 21 May 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion" or the “Company”) is pleased to announce that that Pareto Securities has published a new analyst newsflash following the Company’s recently reported Q1 2025 financial results and clinical trial developments.
In the report, Pareto Securities reiterated their "Buy" recommendation with an unchanged price target of SEK 303 per share. Key highlights from the report include:
- ExpreS2ion’s Q1 2025 cash position stood at SEK 58 million, with expectations for sufficient cash runway into next year.
- Management reaffirmed expected timelines for the flagship ES2B-C001 breast cancer vaccine asset, targeting a potential Phase II initiation in 2027 pending successful Phase I data.
- An amendment request to the clinical trial protocol has been submitted, aiming to enable combination therapy with antibody-drug-conjugates and expand referral centre networks, anticipated to be approved in Q3 2025.
- The analyst expects this protocol amendment to potentially expedite patient recruitment significantly.
- The recent Letter of Intent with WuXi Vaccines was noted for its potential strategic and revenue-generating opportunities from next year.
The full Pareto Securities report, along with previously published analyst reports about ExpreS2ion, is available on the company’s investor website here: Analyst Reports.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB